The "Biologics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global ...

Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

Revolution Medicines' promising KRAS inhibitors show potential in pancreatic cancer. See why we recommend a hold rating on ...

In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report), ...

PORTLAND, IA, UNITED STATES, January 28, 2025 /EINPresswire / -- According to the report, the global biosimilars <a target=_blank href= ...

Guggenheim Securities SMID Cap Biotech Conference Format: Fireside Chat and one-on-one investor meetings Presentation Date: February 5, 2025 Presentation Time: 2:30 PM Webcast: Click here ...

Commit Biologics ("Commit"), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today announces a ?5.5m extension to its seed financing. The contribution from ...

Investment analysts at HC Wainwright issued their FY2024 earnings per share estimates for Genmab A/S in a report issued on ...

Additional funding from new investor Korys, joining existing syndicate members Novo Holdings and Bioqube Ventures, brings total seed financing to €21.5mFunds will be used to further develop ...

Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that the positive reimbursement decision for its drug Pepaxti (melflufen) has been published in the ...